Is ibrutinib/ibrutinib a domestic drug or an imported drug?

Ibrutinib/Ibrutinib (Ibrutinib) is an imported original drug developed by the American pharmaceutical company Pharmacyclics. Ibrutinib was first approved by the U.S. FDA in April 2014 and was quickly used globally, especially in the treatment of B cell-related malignant tumors such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).

In China, the imported original version of ibrutinib has been approved and included in medical insurance, which has greatly promoted the popularity and application of this drug. Taking the specification of 140mg*90 tablets as an example, the imported version of ibrutinib is priced at more than 10,000 yuan. Although the price is higher, medical insurance coverage allows more patients to obtain this targeted therapy, improving their treatment options and quality of life.

In addition to imported original drugs, generic drugs of ibrutinib have also been launched globally and are gradually appearing on the market. Chinese pharmaceutical companies have also begun to develop domestic versions of ibrutinib, which are usually highly consistent with the original drug in terms of ingredients, dosage forms and efficacy, and can provide patients with more economic choices. It is expected that more domestically produced ibrutinibs with price advantages will be launched in the next few years. These generic drugs and domestically produced drugs provide Chinese patients with more choices, help reduce the overall cost of drug treatment, and further promote the popularity of targeted therapy drugs.

Generally speaking, as a targeted therapy drug, ibrutinib was initially an imported original drug. Currently, there are both imported and domestic versions in the domestic market. With the emergence of domestically produced drugs, the price of ibrutinib has gradually become more affordable, allowing more patients to afford it and benefit from its remarkable efficacy.

Reference materials:https://www.imbruvica.com/